EMICERFONT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24N6O2
Molecular Weight	404.465
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(C)=C(C=C1)N2CCC3=C2N=C(C)C=C3N4C=CC(=N4)N5CCNC5=O

InChI

InChIKey=JFHJGXQFESYQGY-UHFFFAOYSA-N

InChI=1S/C22H24N6O2/c1-14-12-16(30-3)4-5-18(14)26-9-6-17-19(13-15(2)24-21(17)26)28-10-7-20(25-28)27-11-8-23-22(27)29/h4-5,7,10,12-13H,6,8-9,11H2,1-3H3,(H,23,29)

HIDE SMILES / InChI

Molecular Formula	C22H24N6O2
Molecular Weight	404.465
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18989952 | https://adisinsight.springer.com/drugs/800016136

Emicerfont (GW876008) is a nonpeptide vcorticotropin-releasing factor type 1 (CRF1) receptor antagonist. It was in clinical trials for the treatment of anxiety disorders, irritable bowel syndrome and major depressive disorder however development of emicerfont has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Corticotropin-releasing factor receptor 1 3 Target ID: P34998 Gene ID: 104909134\|\|\|1394 Gene Symbol: CRHR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18989952	Antagonist 2778		66.0 nM [IC50]

PubMed

Title	Date	PubMed
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.	2008 Dec 11	18989952
Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain.	2011 Aug 31	21880911
Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome.	2013 Dec	23954313
Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.	2013 Mar 1	23294766

Patents

Sample Use Guides

In Vivo Use Guide

a single-center, randomized, double-blind, 3-period crossover study of 11 women with irritable bowel syndrome and 15 healthy women (controls) given a single oral dose (20 mg or 200 mg) of emicerfont (GW876008) or placebo

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:12:37 GMT 2023` Edited by `admin` on `Fri Dec 15 16:12:37 GMT 2023`
Record UNII	OJ8EG4264P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMICERFONT

Official Name

English

GW-876008X

Code

English

1-(1-(1-(4-METHOXY-2-METHYLPHENYL)-6-METHYL-2,3-DIHYDRO-1H-PYRROLO(2,3-B)PYRIDIN-4-YL)- 1H-PYRAZOL-3-YL)IMIDAZOLIDIN-2-ONE

Systematic Name

English

GW876008

Code

English

GW-876008

Code

English

EMICERFONT [USAN]

Common Name

English

2-IMIDAZOLIDINONE, 1-(1-(2,3-DIHYDRO-1-(4-METHOXY-2-METHYLPHENYL)-6-METHYL-1H- PYRROLO(2,3-B)PYRIDIN-4-YL)-1H-PYRAZOL-3-YL)-

Systematic Name

English

GW876008X

Code

English

emicerfont [INN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C174801